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Introduction Newborn screening (NBS) for CF is not available in Sweden. The
aim was to study age at diagnosis and factors associated with disease progression.
Methods 119 patients from the Stockholm CF centre registry met the inclusion
criteria: born 1974–2001, a ﬁrst visit at the centre within 6 months from diagnosis,
at least two annual controls. We studied lung, liver and nutritional morbidities
separately and together. The patients were followed from: 1) healthy at diagnosis
to endpoint symptoms of morbidity and 2) symptoms of morbidity at diagnosis to
endpoint free of morbidity. The deﬁnitions were; “lung morbidity”: pathological
pulmonary X-ray or scintigraphy (<7 y) or FEV1 <85% of predicted (>7 y),
“liver morbidity”: pathological ultrasonography or elevated ALT/g-GT, “nutritional
morbidity”>: weight or height below −0.5 SD from the birth weight or height
(<18 y) or BMI< 18.5 (18 y). We employed Kaplan–Meier survival curves and
proportional hazards regression to investigate factors possibly affecting time to each
endpoint.
Results Median age at diagnosis was 5.0 months. The patients with symptoms of
any morbidity and >24 months at diagnosis had a decreased risk to ever become
free of morbidity (HR 0.14, 95%CI 0.04−0.45) compared to those diagnosed at
2−12 months. The patients healthy in all morbidities at diagnosis had a decreased
risk to reach the endpoint symptoms of any morbidity given the diagnosis with >12
months of delay (HR 0.03, 95%CI 0.00−0.50) compared to those with 0−2 months
delay.
Conclusions The study indicates a disadvantage for patients who at diagnosis were
>24 months and had symptoms of lung, liver or nutrition morbidity. It is important
to ﬁnd these patients earlier, this might favour NBS.
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Introduction: Air pollution leads to increased airway inﬂammation and exacer-
bations in asthma. Goss et al found higher background levels of particulate air
pollution to be associated with increased exacerbations and a decline in lung
function in cystic ﬁbrosis (CF) patients [1]. Our aim was to assess whether an urban
environment or proximity to a major A-road increased pulmonary exacerbations or
the need for bronchodilator therapy in CF patients.
Methods: Data was collected on 300 adult CF patients. A geographic information
system was used to assess home location and proximity to a major A-road. Patients
were deﬁned as living in an urban area if they lived within the inner city ring
road of one of three major cities in Yorkshire. Notes were reviewed to calculate
the frequency of pulmonary exacerbations requiring intravenous antibiotics over a
1 year period from December 2006. The usage of inhaled steroid and long-acting
beta-agonists were noted.
Results: No statistical difference in exacerbation rates and inhaled treatment was
found between the groups (see Table 1).
Discussion: It is likely that any contribution of the urban environment and pollution
is minimal compared with other variables such as severity of lung disease and
organisms grown.
Table 1.
Environment (No. of pts) Median annual infective exacerbations
(range)
Inhaled
steroid
Inhaled long-acting
beta-agonist
Urban vs Non-urban
Non-urban (208) 2.1 (0−12) 115 (55%) 112 (53%)
Urban (92) 2.1 (0−12) 44 (48%) 41 (45%)
P-value NS NS NS
Distance from A-road
<50m from A-road (39) 2.1 (0−12) 22 (56%) 21 (54%)
>300m from A-road (186) 1.7 (0−12) 83 (53%) 74 (47%)
P-value NS NS NS
Reference(s)
[1] Goss et al. Am J Resp Crit Care Med 2004; 169: 816–821.
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CF is the most common inherited disease in the UK with approximately 7,500
sufferers. Currently there is only one UK adult CF QoL instrument. Previous
work found several shortcomings (eg inappropriate frame of reference, scaling and
format; long statements; lack of positive statements and content validation) and
therefore the aim was to develop a new instrument.
75 patients, 26 relatives and partners were interviewed on how CF affected their
day to day life. A focus group was held with 9 members of the CF team to ﬁnd
out what areas of life they felt CF affected. Item generation involved inclusion of
all signiﬁcant domains. A developmental construct was created which underwent
content validation.
Following conceptualisation, item generation, item reduction phases of the study,
the ﬁrst version of the Adult CF QoL Proﬁle (ACFQP) was developed consisting
of 36 items grouped into 9 domains. This was tested for content validity using
a 7 member panel of judges. Rating of 36 ACFQP items on 4 criteria (language
clarity, completeness, relevance, scaling) examining appropriateness of focus and
emphasis of the measure for intended population was followed by a panel discussion
to consider suggested changes. Final changes to ACFQP included: removal of ‘a bit
of the time’ from response options; increase of response options from 5 to 6 to
avoid middle point effect; mixing positive/negative statements to remove negative
impact of questionnaire completion on patients’ mood. Agreement among panel
members was tested and revealed kappa coefﬁcient 0.58.
The importance of this work is to help CF patients get the best from their treatment
by enabling the care team to treat them in a holistic manner and tailor treatment to
patient-reported outcomes.
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Aim: Brittany was among the ﬁrst areas in Europe to implement newborn screening
(NBS) for CF (in 1989). This study describes the death rate and the survival in
the cohort of patients screened in Brittany, and compares them to those observed
previously.
Method: A before-after study was performed to compare these indicators in two
cohorts: the cohort of screened patients (period 1989–2006) and one cohort of
patients born prior to NBS (period 1970–1986). Patients’ vital statute was obtained
by CF centres, French CF Registry and/or birth councils.
Results: Over the period 1989–2006, 228 CF patients were screened in Brittany,
among whom nine died over that period (death rate: 4.0%). Most of these deaths
occurred in early ages and four were not consecutive to CF. Over the previous
period of same duration (1970–1986), we registered 295 patients diagnosed with CF.
Among them, 66 died over that 18-year period (death rate: 22.4%). The death
rate was thus more than ﬁve times lower in the screened group (c2 = 35.5,
OR= 0.14 [0.06; 0.30], p< 0.0001). The survival curve was also signiﬁcantly better
in that group (log-rank: p< 0.0001). This ﬁnding remained unchanged by excluding
patients with mild genotypes.
Conclusion: This study clearly illustrates improvement in survival of CF patients
which results from a combination of factors (better multidisciplinary management
in CF centres, early diagnosis, improvement in treatments, . . . ).
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